Press release
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
- Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- Topline Results from PROSERA Phase 3 Expected in February 2026 -\n\n- First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD -\n\n- Cash, cash equivalents and marketable securities totaled $180 million as of September 30 -\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.\n\n“We are proud to be progressing through the final stages of the PROSERA Phase 3 Study. This is a pivotal moment for our team, and I am continually impressed by the focus, diligence, and professionalism that everyone brings to this important work. We look forward to sharing top-line results with the community in February of next year,” said Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio.\n\n“At the same time, we are encouraged by the engagement from the PH-ILD community as we begin to activate the first clinical sites in the SERANATA Phase 3 study. We are grateful for the opportunity to collaborate closely with physicians and patients to better understand the challenges for those living with this challenging and under-treated disease. We are excited to begin enrollment, and we are hopeful that our collective efforts will ultimately improve the lives of patients living with PH-ILD.”\n\nSeralutinib (GB002): Inhaled PDGFR, CSF1R and c-KIT Inhibitor\n\nSeralutinib: Pulmonary Arterial Hypertension\n\n\nOn June 11th, we completed enrollment for the ongoing Phase 3 PROSERA Study with 390 WHO Functional Class II and III PAH patients. The PROSERA Study is a double-blind, placebo-controlled, global registrational clinical trial evaluating seralutinib in PAH patients, on top of background PAH therapy. Patients are randomized 1:1 to either the seralutinib or placebo arms. Patients received blinded treatment for up to 48 weeks.\n\n\nThe primary endpoint of the PROSERA Study is change in six-minute walk distance (6MWD) from baseline as compared to p...